Seaport Therapeutics (NASDAQ:SPTX) Earns Outperform Rating from Analysts at Leerink Partners

Stock analysts at Leerink Partners initiated coverage on shares of Seaport Therapeutics (NASDAQ:SPTX) in a research report issued to clients and investors on Tuesday. The firm set an “outperform” rating and a $35.00 price target on the stock. Leerink Partners’ price objective suggests a potential upside of 100.00% from the stock’s current price.

A number of other research firms also recently issued reports on SPTX. BNP Paribas Exane downgraded Seaport Therapeutics to a “market perform” rating in a research note on Tuesday. Seaport Research Partners set a $42.00 target price on Seaport Therapeutics in a research report on Tuesday. Stifel Nicolaus set a $30.00 target price on Seaport Therapeutics and gave the company a “buy” rating in a research report on Tuesday. Citigroup assumed coverage on Seaport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. Finally, Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Seaport Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.50.

Seaport Therapeutics Price Performance

SPTX stock opened at $17.50 on Tuesday. Seaport Therapeutics has a 1 year low of $14.85 and a 1 year high of $23.00.

Insider Activity at Seaport Therapeutics

In other Seaport Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 1,100,000 shares of the stock in a transaction dated Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the transaction, the insider directly owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. The trade was a 21.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.